Business Wire

CA-G2-RISK-SOLUTIONS

4.3.2024 14:09:28 CET | Business Wire | Press release

Share
G2 Risk Solutions and Mastercard Combine AI and Merchant Insights for Superior Transaction Laundering Detection

G2 Risk Solutions (G2RS), the leading provider of merchant risk intelligence for the global payments industry, is partnering with Mastercard to provide merchant acquirers with a more streamlined experience to help them reduce transaction fraud.

Transaction laundering (TL) is a type of fraud in which a registered merchant account is used to process sales of illegal goods and services. These accounts are being used fraudulently by bad actors whose activity puts legitimate payment providers at significant financial and reputational risk.

This collaboration adds Mastercard’s powerful Brighterion Artificial Intelligence (AI) technology to G2RS’ end-to-end transaction laundering detection solution to address evolving risk associated with increased criminal activity.

G2RS will offer a leading merchant risk solution backed by:

  • Mastercard Brighterion AI models, offering transaction-level fraud screening and merchant risk scores
  • The G2RS Merchant Map®

The unrivaled G2RS Merchant Map includes 20 years of unique merchant data, including billions of data points validated by expert analysts. It provides the industry's best-in-class known-launderer database, protecting clients throughout the entire merchant lifecycle.

In combination with Mastercard’s AI-driven fraud scores the G2RS merchant risk solution suite introduces the marketplace’s first comprehensive view of merchant activity for enhanced transaction laundering detection. At the same time the solution will simplify payments providers’ workflows.

Rohit Chauhan, EVP, Mastercard Cyber and Intelligence, said: “At Mastercard we’re providing world-leading AI capabilities offering a streamlined experience that protects customers from fraud. Through this partnership with G2RS, acquirers will benefit from additional intelligence to help them reduce transaction fraud. It is yet another step in our journey to secure the payments ecosystem and instill trust in every interaction. "

Rochelle Blease, President, G2 Risk Solutions, said: “Payments risk evolves rapidly, and it demands bolder moves to counter bad actors. By aligning the industry’s data insights, we are equipping the payments industry with much stronger and more comprehensive defenses to identify merchant health signals and protect the integrity of the payments ecosystem.”

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240304550784/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SymphonyAI Launches Eight AI Applications Purpose-Built for Energy Asset Reliability and Operational Performance20.4.2026 07:09:00 CEST | Press release

Eight AI applications engineered for asset reliability, operational performance, and emissions obligations SymphonyAI, a global leader in Vertical AI platforms, today announced eight new industrial AI applications purpose-built for energy operators, marking the most targeted expansion of IRIS Foundry into the energy sector to date. Unlike generic asset management software, these applications are engineered around the specific failure modes, process dynamics, and regulatory obligations of energy and resources operations — compressor surge, heat exchanger fouling, pipeline integrity degradation, refinery unit yield loss, and the growing compliance burden of EU methane regulation and emissions reporting. By combining SymphonyAI’s deep industrial ontology with IRIS Foundry’s ability to unify IT, OT, and IoT data from historians, SCADA systems, inspection databases, and enterprise platforms into a single governed intelligence layer, the new suite delivers causal AI at the point where energy

Petronor and H2SITE Partner to Pioneer High-Purity Hydrogen Production in Refining Through Advanced Membrane Technology20.4.2026 07:00:00 CEST | Press release

H2SITE, a technology company specialised in advanced hydrogen production and separation solutions, has signed a strategic agreement with Petronor, a leading refinery and key industrial player in the energy sector with a clear commitment to achieving net-zero emissions, to deploy its high-efficiency hydrogen separation technology at Petronor’s refinery. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260419792308/en/ The partnership sets the stage for the joint development of a pioneering First-of-a-Kind (FOAK) unit, integrating H2SITE’s proprietary membrane technology into the Steam Methane Reforming (SMR) process in refineries to improve overall plant efficiency, enhance CO₂ capture opportunities, and ultimately strengthen operational performance and industrial competitiveness. Petronor’s engineering and operations teams are joining forces with H2SITE’s technical experts, leveraging decades of refinery expertise, industrial

SBC Medical Announces Pricing of Secondary Public Offering of 3.1 Million Shares of Common Stock20.4.2026 01:07:00 CEST | Press release

SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“the Company”), a Management Service Organization operating a wide range of franchise businesses across diverse medical fields, today announced the pricing of the underwritten secondary public offering of 3,100,000 shares of the Company’s common stock by Dr. Yoshiyuki Aikawa (the “Selling Stockholder”) at the public offering price of $3.25 per share. Additionally, the Selling Stockholder has granted the underwriters a 45-day option to purchase up to an additional 465,000 shares of the Company’s common stock. The offering is expected to close on or about April 21, 2026, subject to customary closing conditions. The Company is not selling any shares of its common stock in the offering. The Selling Stockholder will receive all of the proceeds from the offering. Maxim Group LLC is acting as the sole book-running manager and Roth Capital Partners is acting as the co-manager for the offering. The offering is being made pursuant to the Com

Horse Powertrain Reveals X-Range C15 Direct Drive Powertrain for Hybridizing BEV Platforms20.4.2026 01:01:00 CEST | Press release

Horse Powertrain, a global leader in innovative and low-emission powertrain systems, will unveil a new ‘all-in-one’ powertrain at Beijing Auto Show 2026: the X-Range C15 Direct Drive. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260419640202/en/ Left-facing view of the HORSE X-Range C15 Direct Drive The ultra-compact X-Range C15 Direct Drive integrates a full hybrid powertrain – including a 4-cylinder engine, transmission, power electronics, and an electric motor – into a single compact unit with a shared housing, designed to mount to the rear subframe enabling a double isolated installation for best NVH. The X-Range C15 Direct Drive is designed as an ‘all-in-one’ powertrain to replace the rear electric drive unit of an existing BEV platform. It enables an automaker to use a single shared platform for their BEV, HEV, PHEV, and REEV lineups without any significant changes to vehicle design or production environments. The ne

Compass Pathways Commends White House Executive Order to Accelerate Research and Access for Psychedelic Treatments18.4.2026 22:12:00 CEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, welcomes the White House Executive Order on accelerating medical treatments for serious mental illness. “We commend the Administration’s Executive Order on psychedelic treatment which recognizes the profound urgency of the mental health crisis facing millions of Americans and the potential impact FDA-approved psychedelics could have,” said Kabir Nath, CEO at Compass Pathways. “Today’s announcement aligns regulatory urgency with patient need, and we applaud the Administration for taking this important step forward in accelerating access, without compromising rigorous science. Compass is conducting the largest, most robust classic psychedelic studies to date with COMP360 synthetic psilocybin. We have recently reported two positive phase 3 trials in treatment-resistant depression (TRD) with highly statistically significant and clinically meaningful data that

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye